Literature DB >> 28713679

Targeting eukaryotic protein translation in mesothelioma.

Robert A Kratzke1.   

Abstract

The default mechanism for protein translation in eukaryotes involves activation of the eIF4 complex at the 5' end of mRNA. This activity is upregulated in cancers, resulting in the expression of a variety of proteins necessary for the development and maintenance of the neoplastic state. Not surprisingly, mesothelioma demonstrates this same reliance on activation of 5' cap mediated translation. Efforts are ongoing to target and exploit our knowledge of this key molecular switch for cancer therapy. Agents targeting the critical eIF4E cap binding protein, disruption of the eIF4 complex, and exploitation for oncolytic virotherapy are some of the important areas of current research in mesothelioma protein translational research.

Entities:  

Keywords:  Eukaryotic initiation factor 4 (eIF4); eukaryotic initiation factor 4E (eIF4E); mesothelioma; protein; translation

Year:  2017        PMID: 28713679      PMCID: PMC5504115          DOI: 10.21037/tlcr.2017.06.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  28 in total

1.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap.

Authors:  A Lazaris-Karatzas; K S Montine; N Sonenberg
Journal:  Nature       Date:  1990-06-07       Impact factor: 49.962

2.  A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

Authors:  Daniel H Sterman; Andrew Haas; Edmund Moon; Adriana Recio; Daniel Schwed; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Emmanouil Papasavvas; Luis J Montaner; Daniel F Heitjan; Leslie Litzky; Joseph Friedberg; Melissa Culligan; Carl H June; Richard G Carroll; Steven M Albelda
Journal:  Am J Respir Crit Care Med       Date:  2011-06-03       Impact factor: 21.405

3.  Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.

Authors:  Bryan A Whitson; Blake A Jacobson; Sandra Frizelle; Manish R Patel; Douglas Yee; Michael A Maddaus; Robert A Kratzke
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

4.  Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes.

Authors:  Chuong D Hoang; Xihong Zhang; Paul D Scott; Tenner J Guillaume; Michael A Maddaus; Douglas Yee; Robert A Kratzke
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.

Authors:  Blake A Jacobson; Michael D Alter; Marian G Kratzke; Sandra P Frizelle; Ying Zhang; Mark S Peterson; Svetlana Avdulov; Riikka P Mohorn; Bryan A Whitson; Peter B Bitterman; Vitaly A Polunovsky; Robert A Kratzke
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Authors:  Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas M Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP.

Authors:  Yan Jia; Ting-Lan Chiu; Elizabeth A Amin; Vitaly Polunovsky; Peter B Bitterman; Carston R Wagner
Journal:  Eur J Med Chem       Date:  2009-12-06       Impact factor: 6.514

8.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

9.  Transforming Growth Factor-β1 Induced Epithelial Mesenchymal Transition is blocked by a chemical antagonist of translation factor eIF4E.

Authors:  K A Smith; B Zhou; S Avdulov; A Benyumov; M Peterson; Y Liu; A Okon; P Hergert; J Braziunas; C R Wagner; Z Borok; P B Bitterman
Journal:  Sci Rep       Date:  2015-12-18       Impact factor: 4.379

View more
  3 in total

1.  4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.

Authors:  Blake A Jacobson; Zeeshan Ahmad; Sierra Chen; Gabriella Waldusky; Maxwell Dillenburg; Emilia Stoian; Daniel A Cambron; Anil J Patel; Manish R Patel; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2020-11-23       Impact factor: 3.850

2.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

3.  Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma.

Authors:  Zeeshan Ahmad; Blake A Jacobson; Mitchell W McDonald; Nicolas Vattendahl Vidal; Gabriel Vattendahl Vidal; Sierra Chen; Maxwell Dillenburg; Aniekan M Okon; Manish R Patel; Carston R Wagner; Robert A Kratzke
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-23       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.